New hope for rare disorder: testing drug to prevent dangerous blood sugar drops
NCT ID NCT07097311
Summary
This study is testing if a medication called triheptanoin is safe and can help prevent low blood sugar (hypoglycemia) in people aged 4 and older with Medium-chain Acyl-CoA Dehydrogenase Deficiency (MCADD), a rare inherited metabolic disorder. Researchers will monitor participants' blood sugar levels continuously for about 8 weeks to see if the drug helps keep levels stable. The main goal is to check for any side effects while also seeing how well the treatment works.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MEDIUM CHAIN ACYL COA DEHYDROGENASE DEFICIENCY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Children's Hospital of Pittsburgh of UPMC
RECRUITINGPittsburgh, Pennsylvania, 15224, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.